Heart Failure Clinical Trial
— DoBHFOfficial title:
Randomized-Controlled-Double Blind Trial of Low Dose Dobutamine in Advanced Heart Failure Patients in a Day-Care Clinic
Verified date | August 2013 |
Source | Sheba Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | Israel: Ethics Commission |
Study type | Interventional |
Heart failure (HF) is a prevalent disease reaching 1-2% of adult population in developed
countries, and 10% in patients over 70 years. In the past HF patients had a 5-year mortality
rate of 60-70% of HF with high rate of hospitalization and disability leading to a HF
epidemic. Treatment improvements in the past decades have significantly reduced
hospitalization and mortality. However, there is an increasing subset of patients (>10%)
with advanced HF symptoms (functional class III/IV) for whom current management strategies
are limited and do not provide a significant improvement in morbidity, mortality and quality
of life.
Specialized HF clinics, implementing a comprehensive therapeutic approach, were suggested to
be beneficial in this population. However, the design of these clinics is variable with
different methods of follow-up, therapy and supervision. Intermittent infusions of
dobutamine were previously inconclusive regarding symptom alleviation and hemodynamic
improvement and raised a concern of increased mortality in HF patients. Furthermore, the
evidence scope is narrow since most trials including inconsistent and relatively high
dobutamine dosages. Accordingly, current guidelines do not provide specific recommendations
for dobutamine therapy in stable HF patients, and indication for treatment are limited for
acute HF with hypotension and signs of hypoperfusion, or alleviation of symptoms in severely
symptomatic patients in stage D HF.
The primary aim of the proposed study is to evaluate the impact of intermittent low-dose
dobutamine infusion on clinical and hemodynamic parameters in advanced HF patients treated
in a tertiary heart failure clinic in the setting of a randomized clinical trial. We
hypothesize that intermittent therapy with low-dose dobutamine will be associated with
improved functional capacity and quality of life among patients with advanced heart failure,
thereby providing evidence for beneficial effects of a potentially important therapeutic
regimen in this high risk population.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | October 2016 |
Est. primary completion date | October 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age over 18 - Symptomatic HF with NYHA III-IV - Left ventricular ejection fraction < 30% - Maximal tolerated dosage of Angiotensin receptor blocker (ARB) or Angiotensin converting enzyme inhibitor (ACEI), aldosterone antagonists and ß-Blockers according to blood pressure, heart rate, renal function and potassium levels - Prior implementation of resynchronization therapy and implantable defibrillator as indicated?? - Prior HF hospitalization in the past 12 months - Unsatisfactory response to intravenous diuretics during hospitalization or ambulatory care. Exclusion Criteria: - Active ischemia - Acute coronary syndrome or cardiac surgery within 3 months - Hemodynamic and respiratory instability, with systolic blood pressure below 85mmHg, and oxygen saturation below 90% at rest - Uncontrolled hypertension >180/110 mmHg - Contra-indication to dobutamine therapy - Hemodialysis therapy - Malignant ventricular arrythmias - Drug or alcohol abuse - Sepsis or ongoing systemic infection - Active myocarditis - Severe valvular stenosis - Non-compliance - Life-threatening extra-cardiac disease or malignancy with a life expectancy below 1 year - Inability to sign an informed consent - Participation in another trial during the previous 6 months |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Israel | Leviev Heart Center, Chaim Sheba Medical Center | Ramat-Gan |
Lead Sponsor | Collaborator |
---|---|
Sheba Medical Center |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | • Improvement in maximal oxygen consumption (VO2 max) | 6 months and 12 months | No | |
Secondary | • Combined endpoint of heart failure or all-cause mortality at 6 and 12 months of follow-up | 6 and 12 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|